Overview
ACE-031, also known as ActRIIB-IgG1, is a fusion protein and myostatin inhibitor developed for research into muscle growth and related conditions. Myostatin is a naturally occurring protein in the body that limits muscle growth; ACE-031 works by binding to myostatin, preventing it from inhibiting muscle development.
Originally developed for potential therapeutic applications in conditions characterized by muscle wasting, such as muscular dystrophy and age-related sarcopenia, ACE-031 has been investigated for its ability to increase muscle mass and strength. The peptide is created by fusing a portion of the activin receptor type IIB (ActRIIB) to the Fc region of human immunoglobulin G1 (IgG1).
ACE-031 is primarily a research tool. Its use is currently limited to laboratory studies aimed at understanding muscle biology, metabolic processes, and potential cancer-related applications.
Mechanism of Action
ACE-031 functions by targeting myostatin, a key negative regulator of muscle mass. Myostatin inhibits muscle growth by binding to the ActRIIB receptor on muscle cells, triggering a signaling cascade that limits protein synthesis and muscle cell proliferation. ACE-031 acts as a decoy receptor.
By binding to myostatin, ACE-031 prevents myostatin from interacting with the ActRIIB receptor on muscle cells. This disruption of myostatin signaling allows for increased muscle protein synthesis and muscle growth. The Fc portion of IgG1 in ACE-031 enhances its stability and half-life in circulation, prolonging its inhibitory effect on myostatin.
Key Benefits
- Increased Muscle Mass
- Potential Metabolic Benefits
- Research Applications in Cancer Studies
Research & Indications
Research on ACE-031 has primarily focused on its potential to treat conditions associated with muscle wasting. Studies have explored its effects on muscle mass, strength, and functional outcomes in preclinical models. Additionally, ACE-031 has been investigated for its potential role in metabolism and cancer research.
In preclinical studies, ACE-031 has demonstrated the ability to promote significant increases in muscle mass and strength. These findings suggest its potential as a therapeutic agent for muscular dystrophy, sarcopenia, and other muscle-wasting disorders. Research has also explored its impact on glucose metabolism and insulin sensitivity, indicating potential benefits for metabolic disorders.
Furthermore, ACE-031 has been investigated in the context of cancer research, particularly in relation to cancer-induced cachexia (muscle wasting). By inhibiting myostatin, ACE-031 may help counteract muscle loss in cancer patients, improving their quality of life and treatment outcomes. Note that most of these studies are in pre-clinical phases.
Dosing Protocols
Disclaimer: The following dosing information is for research purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before using any research peptide.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Muscle Growth | 1-3 mg | 1-2x weekly | SubQ or IM |
Supplies Needed
For an 8–16 week research protocol:
Peptide Vials: 8–24 vials (depending on 1mg vs 3mg dosage and duration).
Insulin Syringes (U-100): 1–2 per week (roughly 10–35 total for the full cycle, including extras).
Bacteriostatic Water: 1–2 × 10mL bottles.
Alcohol Swabs: 2 per injection (one for the vial, one for the site).
Side Effects & Safety
Side effects associated with ACE-031 are not well-documented due to the limited scope of human studies. Potential side effects may include injection site reactions, muscle pain, and changes in bone metabolism. Given its mechanism of action, there may also be unforeseen effects on other growth factors and signaling pathways in the body.
Due to its broad binding profile (it binds to more than just myostatin), researchers have noted specific side effects in past clinical trials:
Minor nosebleeds and gum bleeding (the primary reason some human trials were halted).
Telangiectasia (small dilated blood vessels on the skin).
Injection site irritation or muscle soreness.
Storage & Handling
ACE-031 should be stored lyophilized (freeze-dried) at -20°C until ready for use. Reconstitution should be performed with bacteriostatic water. After reconstitution, the peptide should be refrigerated at 2-8°C and used within a reasonable period (e.g., within 30 days) to maintain stability.